# Zanubrutinib-rituximab(ZR) in Patients With Newly Diagnosed Untreated Mantle Cell Lymphoma

> **NCT05504603** · PHASE2 · UNKNOWN · sponsor: **The First Affiliated Hospital of Soochow University** · enrollment: 20 (estimated)

## Conditions studied

- Untreated Mantle Cell Lymphoma

## Interventions

- **DRUG:** zanubrutinib and rituximab
- **DRUG:** zanubrutinib and rituximab
- **DRUG:** BEAM pretreatment
- **DRUG:** zanubrutinib maintenance

## Key facts

- **NCT ID:** NCT05504603
- **Lead sponsor:** The First Affiliated Hospital of Soochow University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-07-27
- **Primary completion:** 2023-07-26
- **Final completion:** 2025-07-26
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2022-08-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05504603

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05504603, "Zanubrutinib-rituximab(ZR) in Patients With Newly Diagnosed Untreated Mantle Cell Lymphoma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05504603. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*